Authors: Cunningham, CC Holmlund, JT Geary, RS Kwoh, TJ Dorr, A Johnston, JF Monia, B Nemunaitis, J

Citation: Cc. Cunningham et al., A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma, CANCER, 92(5), 2001, pp. 1265-1271

Authors: Holmlund, JT

Citation: Jt. Holmlund, Clinical activities in patients with solid tumors or lymphoma, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 739-759

Authors: Cunningham, CC Holmlund, JT Schiller, JH Geary, RS Kwoh, TJ Dorr, A Nemunaitis, J

Citation: Cc. Cunningham et al., A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer, CLIN CANC R, 6(5), 2000, pp. 1626-1631

Authors: Yuen, AR Halsey, J Fisher, GA Holmlund, JT Geary, RS Kwoh, TJ Dorr, A Sikic, BI

Citation: Ar. Yuen et al., Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer, CLIN CANC R, 5(11), 1999, pp. 3357-3363

Authors: Nemunaitis, J Holmlund, JT Kraynak, M Richards, D Bruce, J Ognoskie, N Kwoh, TJ Geary, R Dorr, A Von Hoff, D Eckhard, SG

Citation: J. Nemunaitis et al., Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer, J CL ONCOL, 17(11), 1999, pp. 3586-3595

Authors: Miller, LL Korn, EL Stevens, DS Janik, JE Gause, BL Kopp, WC Holmlund, JT Curti, BD Sznol, M Smith, JW Urba, WJ Donegan, SE Watson, TM Longo, DL

Citation: Ll. Miller et al., Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin, BLOOD, 93(10), 1999, pp. 3250-3258